Efficacy and Safety of Risankizumab Compared with Apremilast in Patients with Moderate Plaque Psoriasis: Mean PASI and BSA Results From the Phase 4 IMMpulse Trial. J of Skin. 2023;7(6):s257. doi:10.25251/skin.7.supp.257